The effect of fluconazole prophylaxis on the vaginal flora of 323 human immunodeficiency virusinfected women was evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. Women with CD4 cell counts of £300/mm 3 received either 200 mg of fluconazole per week or placebo. Vaginal surveillance cultures were performed every 3 months. After a follow-up of 29 months, Candida albicans was recovered from 53% of patients receiving fluconazole and 68% of patients assigned placebo. Fluconazole was associated with a 50% reduction in the odds of being colonized with C. albicans but with higher rates for non-albicans Candida species. Candida glabrata was recovered from 40 women assigned fluconazole and 29 assigned placebo (relative odds, 1.96; 95% confidence interval, 0.98 -3.94). Fluconazole had an early and persistent effect on the vaginal mycoflora, with the emergence of C. glabrata vaginal colonization within the first 6 months. The effect of fluconazole prophylaxis can be attributed to the reduction in vaginal C. albicans colonization; however, C. glabrata colonization rapidly supervened.
Fungal infections are among the most common opportunistic
Previously, only alterations in the gastrointestinal microbial flora of hospitalized neutropenic patients receiving long-term complications in persons infected with HIV type 1 (HIV) [1, 2] . The most frequently encountered fungal infections are suantifungal therapy have been described [14, 15] . We recently reported the results of a double-blind, placeboperficial (mucosal) infections, produced by opportunistic fungal pathogens belonging to the Candida species [1 -4] .
controlled trial of fluconazole, in a weekly dose of 200 mg, in preventing mucosal candidiasis in HIV-infected women with Fluconazole, a broad-spectrum systemic antifungal, is highly effective for the treatment of acute mucocutaneous candidiasis CD4 / cell counts of õ300/mm 3 [12] . The main findings of the study carried out by the Terry Beirn Community Programs in patients with AIDS, producing a more rapid clinical and mycologic response than observed with other azoles [5 -7] . In for Clinical Research on AIDS (CPCRA) were that weekly fluconazole was effective in preventing symptomatic oropharaddition, daily or intermittent doses of fluconazole have been shown to be effective in preventing mucosal candidiasis in yngeal and vaginal candidiasis over a 29-month follow-up. In addition, rates of clinical and in vitro fluconazole resistance AIDS patients [8 -13] . Nevertheless, use of fluconazole as both primary and secondary prophylaxis for fungal infections is conwere low and did not vary by treatment group. In addition, preliminary analysis of vaginal surveillance specimens coltroversial and generally not recommended because of cost, drug interactions, and risk of antifungal resistance in Candida spelected every 3 months revealed reduced rates of colonization with C. albicans and increased isolation of Candida species cies [13] .
Despite the high prevalence rates of mucosal candidiasis and other than Candida albicans in the fluconazole group vs. the placebo group. This study extends the findings of our initial the frequent, long-term use of antifungals, no large prospective studies have evaluated the long-term effect of antifungals on report investigating the rates of vaginal colonization for C. albicans, Candida glabrata, and other Candida species by comparmucosal fungal flora in patients with HIV infection or AIDS.
ing changes over time in colonization rates between treatment groups and assessing the determinants of rates of vaginal colonization in HIV-positive women. effect of fluconazole prophylaxis on colonization rates. In both per-patient and per-culture analyses, follow-up was censored at the last 3-month follow-up examination at which a surveillance culture was obtained. Both intention-to-treat Results (according to randomized assignment, irrespective of use of blinded study medication) analysis and during-treatment Baseline colonization. The randomized groups were well matched at enrollment [12] . Three hundred and twenty-three (with prescribed blinded study medication) analyses were carried out. In the latter, cultures obtained while the patient women were enrolled, and 162 were randomized to receive fluconazole and 161 to receive placebo; 65% were black and was taking an open-label antifungal for episodic treatment of candidiasis were not considered, and follow-up was cen-20% were Hispanic. The median CD4 / cell count was 180/mm 3 ; 25% had previously diagnosed AIDS. A history of sored at the last follow-up visit at which a vaginal culture specimen was obtained and at which blinded study medicamucosal candidiasis was reported by 70% of women; oral candidiasis was reported by 47%; and an episode of vaginal candition was prescribed. All analyses controlled for the center where the patient was enrolled and included baseline covaridiasis in the past year was reported by 53%. Baseline culture results were similar in the two treatment ates. The covariates included the isolation of C. albicans, C. glabrata, and other Candida species at enrollment, CD4 / groups (table 1) . Overall, 109 of 323 women randomized (34%) had a positive baseline vaginal culture. C. albicans was isolated cell count, and history of mucosal candidiasis; associations are expressed as odds ratios (fluconazole vs. placebo) with from 69% of positive cultures, C. glabrata from 21%, other non-albicans Candida species from 8%, and other fungal spetwo-sided P values and 95% confidence intervals.
To determine whether differences in vaginal colonization cies from 5%. Specimens from which more than one fungal species were recovered simultaneously (mixed cultures) were between the fluconazole and placebo groups varied over followup, the percentages of women colonized with C. albicans and rare and were obtained from only three women at baseline. Within 30 days before randomization, 5% of patients had C. glabrata were estimated for each 6-month interval of followup and odds ratios (fluconazole vs. placebo) were calculated used systemic antifungal prophylaxis and 12% had received systemic antifungal treatment. Nine percent of patients reported by means of logistic regression. using topical antifungal treatment at the time of randomization. The exclusion of women taking systemic or topical antifungal medication did not substantially alter the baseline culture results shown in table 1. Overall, 79 of 253 women (31.2%) had a positive culture. C. albicans was isolated in 68% of positive cultures, C. glabrata in 22%, other Candida species in 6%, and other fungal species in 6%.
In a multivariable logistic regression analysis that included covariates corresponding to race, CD4
/ cell count, and history of mucosal candidiasis, only the baseline CD4
/ cell count was significantly associated with having a positive culture for yeast at baseline. A decrease in the CD4
/ cell count of 50/mm 3 was associated with an 11% increase in the likelihood of having a The median follow-up was 29 months, and the median duration the fluconazole recipients than among placebo recipients (P Å .17 for log-rank statistic). Most of this difference was of blinded medication was 17 months for patients assigned fluconazole and 10 months for those assigned placebo. A total due to a higher rate of C. glabrata recovery in the fluconazole group than in the placebo group. By 12 months, 17% of women of 76 patients received open-label fluconazole, 29 (18%) in the fluconazole group and 47 (29%) in the placebo group. Among assigned fluconazole and 12% of women assigned placebo had C. glabrata isolated at least once following randomization. The the 162 women assigned weekly fluconazole prophylaxis, 153 (94%) had at least one vaginal surveillance culture performed corresponding recovery percentages by 24 months for C. glabrata were 28% and 21% in the fluconazole and placebo during follow-up; the median number of specimens obtained was seven. Of the women assigned placebo, 145 (90%) had at groups, respectively. Figure 2 summarizes the percentages of women with specific least one surveillance culture performed, and the median number of specimens obtained was six. For patients assigned flucoorganisms isolated in 6-month intervals during follow-up. During the first 6 months of follow-up, 25.7% of patients assigned nazole, 969 vaginal cultures were performed during the followup visits. Thirty-three percent (319) yielded fungi, and a total fluconazole and 46.4% assigned placebo had C. albicans isolated. In each of the next four 6-month follow-up intervals, of 340 isolates were recovered. There were 902 cultures performed in the placebo group; 371 (41%) yielded fungi, and a the percentages of women who had C. albicans recovered, by treatment group (fluconazole vs. placebo), were as follows: total of 388 isolates were recovered. 43.3% at 25 -30 months. The differences in frequency of C. albicans isolation between the fluconazole and placebo groups that were recovered from follow-up cultures, C. glabrata was the most common non-albicans Candida species in both treatwere similar and persisted throughout the entire follow-up period. Odds ratios for C. albicans isolation -adjusted for CD4 / ment groups (28% of cultures in the fluconazole group vs. 16% in the placebo group). Other Candida species besides cell count, history of mucosal candidiasis, and organisms isolated at enrollment -for these five 6-month intervals were 0.40 C. albicans and C. glabrata were uncommon in both treatment groups.
(P õ .001), 0.43 (P Å .004), 0.52 (P Å .03), 0.51 (P Å .04), and 0.48 (P Å .07), respectively. The cumulative percentage of women from whom C. albicans was isolated during follow-up was significantly lower Figure 2 also gives the percentage of women from whom C. glabrata and other non-albicans Candida species were isofor those assigned fluconazole than for those assigned placebo (figure 1; P Å .0001). After 12 months of follow-up, 40% of lated at each 6-month interval. The early differences between the fluconazole and placebo groups for the isolation of nonwomen assigned fluconazole and 63% assigned placebo had C. albicans isolated at least once following randomization.
albicans Candida species persisted. Odds ratios (fluconazole vs. placebo) based on logistic regression for all non-albicans Corresponding percentages after 24 months were 59% and 80% for the fluconazole and placebo groups, respectively. The cuCandida species for the five 6-month intervals were 1.4 
C. glabrata was isolated in eight (20.5%). In contrast, 44
women in the placebo group had 68 confirmed vaginal candidiasis episodes. Of those 68 episodes, C. glabrata was isolated in only three (4.4%). (P Å .39), 1.4 (P Å .41), 3.7 (P Å .006), 1.7 (P Å .22), and 1.3 (P Å .63). Odds ratios for C. glabrata for these five 6-When vaginal isolates obtained during surveillance or event documentation from both treatment groups was considered, month intervals were 1.7 (P Å .26), 1.9 (P Å .21), 3.1 (P Å .03), 1.4 (P Å .48), and 1.0 (P Å .94), respectively. colonization with C. glabrata was significantly less frequently associated with clinical signs and symptoms of vaginal candidiSince there was no evidence of a trend in the relative difference between treatment groups in terms of colonization with asis than was that with C. albicans (17.7% vs. 31.8%; P Å .001). When clinical signs and symptoms were present, either C. albicans or C. glabrata, findings for the entire followup period are summarized in table 2. The upper portion of table C. glabrata isolates were most often associated with white exudate adherent to vaginal mucosa (78.6%) and, to a lesser extent, 2 summarizes the intention-to-treat analysis both for the perpatient (time to first event) analysis and for the per-culture vaginal pruritus (28.6%). When C. albicans was isolated, it was associated with a similar percentage of white exudate analysis (repeated events for each patient are considered). The bottom portion gives similar summary statistics for the during-(61.6%) and pruritus (67.4%). When vaginal candidiasis was suspected, patients were treated equally frequently (70%), treatment analysis. Per the intention-to-treat analysis, 86 of 162 patients (53%) assigned fluconazole had 197 vaginal yeast whether C. glabrata or C. albicans was colonized. Once treated, clinical signs and symptoms more frequently resolved cultures yielding C. albicans, and 110 of 161 patients (68%) assigned placebo had 290 cultures yielding C. albicans. Among for those colonized with C. albicans than for those colonized with C. glabrata (93.4% vs. 75%; P Å .07). Moreover, there the 86 patients in the fluconazole group who had C. albicans isolated at least once, 37 (43%) had just 1 follow-up culture were only two cases of clinical resistance among 78 patients with confirmed vaginal candidiasis; both involved colonization positive for C. albicans; 17 (20%) had 2; 18 (21%) had 3; and 14 (16%) had §4. For the 110 patients in the placebo group with C. glabrata (one in each treatment group). Baseline predictors of colonization during follow-up. Basewho had C. albicans isolated at least once, 42 (38%) had just 1 follow-up culture positive for C. albicans; 23 (21%) had 2;
line predictors of colonization with C. albicans and C. glabrata during follow-up were also evaluated for patients in both treat-18 (16%) had 3; and 27 (25%) had §4. Adjusted odds ratios were 0.45 (95% CI, 0.33 -0.63; P õ .001) and 0.49 (95% ment groups. Among those patients assigned placebo, baseline CD4 / cell count and history of mucosal candidiasis were not CI, 0.35 -0.69; P õ .001) for the per-patient and per-culture analyses, respectively.
significantly associated with the isolation of C. albicans or C. glabrata during follow-up. A decrease in the CD4 / cell Contrasting results were found for the non-albicans Candida species cultures. The odds ratios based on per-patient and percount of 50/mm 3 was associated with a 3% (P Å .51) lower risk of C. albicans isolation and a 5% (P Å .56) lower risk of culture analyses were 1.33 (P Å .21) and 2.00 (P Å .02), C. glabrata isolation during follow-up. The odds ratios for severe and recalcitrant mucocutaneous fungal infections. Both the increased incidence in fungal infections and the consequent C. albicans and C. glabrata associated with a history of mucosal candidiasis were 1.22 (P Å .49) and 0.83 (P Å .75), respecincreased use of antifungals are thought to select for fungal populations that are more resistant to antifungals [19 -22] . Retively.
In the placebo group, the isolation of C. albicans at baseline sistant yeasts, both C. albicans and non-albicans Candida species, are capable of producing debilitating disease that is diffiwas associated with an increased risk of C. albicans colonization during follow-up (OR Å 2.38, P Å .004). The isolation cult if not impossible to eradicate [21, 23] . The use of antifungal prophylaxis to prevent mucocutaneous of C. glabrata at baseline was associated with an increased risk of isolation of C. glabrata during follow-up (OR Å 14.91, candidiasis is still controversial. Leading experts have not advocated the use of antifungal prophylaxis for mucocutaneous P Å .0001), whereas the isolation of C. albicans at baseline was candidiasis as the standard of care for the patient with AIDS not associated with an increased risk of recovery of C. glabrata [24] . The study by Powderly et al. [13] and our earlier report on during follow-up (OR Å 1.16, P Å .81).
the CPCRA trial [12] address some of the key issues regarding For patients assigned fluconazole, as for those assigned plaantifungal prophylaxis for patients with HIV infection or AIDS cebo, there was no association of baseline CD4
/ cell count [12, 13] . Powderly et al. recently performed a prospective, and history of mucosal candidiasis with the isolation of C. albirandomized trial comparing fluconazole (200 mg/d) with clotricans or C. glabrata during follow-up. The isolation of C. albimazole troches [13] . Although the investigators demonstrated cans and C. glabrata at baseline was associated with colonizathat fluconazole use was safe and effective in reducing the tion of C. albicans and C. glabrata during follow-up; however, frequency of systemic and superficial fungal infections, the the association for patients in the fluconazole group was weaker authors did not advocate the use of fluconazole as primary than in the placebo group. The isolation of C. albicans at prophylaxis, except for patients at high risk of fungal disease. baseline was associated with a 64% (OR Å 1.64, P Å .11) Unfortunately, the study did not assess antifungal resistance or increased risk of colonization of C. albicans during follow-up. the evolution of the mycoflora in these patients during antifunOn the other hand, the isolation of C. glabrata at baseline gal therapy. was associated with a threefold increased risk of isolation of
In the CPCRA study, a regimen of once-weekly fluconazole C. glabrata during follow-up (OR Å 3.05, P Å .07).
(200 mg) was safe and effective in preventing oropharyngeal Discussion and vaginal candidiasis, as compared with placebo [12] . Similarly, we concluded in the earlier report that prophylaxis should The population of patients with HIV infection or AIDS constitutes the most rapidly expanding group at risk of developing be considered only for patients who are at high risk for recur-/ 9c65$$my18 04-07-99 09:23:47 cida UC: CID rences. In both instances, the authors expressed concerns re-(less than 36 months), and the dose of fluconazole used in this study. An additional factor that may have affected the isolation garding the impact of antifungal prophylaxis on mucosal fungal flora and hence the emergence of antifungal resistance.
of mixed yeasts was the use of standard yeast-isolation media to recover specimens. In the cross-sectional study by Maenza This is the first study to intensively monitor long-term changes in the vaginal flora of patients receiving antimycotics.
et al. that assessed the microbiology of oral infection in AIDS patients, there was a trend toward the recovery of non-albicans In this further evaluation of a longitudinal multicenter study of HIV-infected women, we show that the use of 200 mg of Candida species alone or in combination with other Candida species when CHROMagar Candida medium (CHROMager fluconazole as weekly prophylaxis, while effective in reducing attacks of symptomatic candidal vaginitis, had a significant Microbiology, Paris) was utilized rather than the standard Sabouraud dextrose agar medium [28] . impact on the vaginal mycoflora.
Results indicate that 200 mg of fluconazole weekly was Schuman et al. [12] found that vaginal candidiasis was confirmed in 18% of cases in which C. albicans alone was recovassociated with a reduction in the rate of vaginal yeast colonization. Specifically, weekly fluconazole decreased the rate of ered from vaginal specimens, in 14% when C. albicans was isolated with another Candida species, and in 5% when only C. albicans isolation by Ç50%. For patients who received fluconazole, however, there was a simultaneous increase in the a Candida species other than C. albicans was recovered. Thus, the clinical significance of the increased isolation of C. glabrata risk of isolation of a non-albicans Candida species, primarily C. glabrata, in comparison with the risk for patients receiving is uncertain.
There are several limitations that should be considered when placebo. Within 6 months after initiation of fluconazole prophylaxis, the overall yeast colonization rate was decreased draevaluating this study. First, although oropharyngeal cultures were performed for patients with documented symptomatic matically; the isolation of C. albicans was decreased by 60%, while the isolation of C. glabrata was ú70% higher in patients oropharyngeal disease, only vaginal cultures were performed in a longitudinal fashion. The evolution of the mycoflora patterns assigned fluconazole than in those assigned placebo. These relative differences between treatment groups in colonization observed in vaginal yeast isolates cannot be extrapolated to the oral or esophageal flora. Second, most of our patients had CD4
/ rates of C. albicans or C. glabrata did not change markedly over a median follow-up of 29 months. Hence, fluconazole cell counts of ú100/mm 3 at enrollment and therefore may have been at lower risk for recurrent episodes of mucosal candidiasis exposure is associated with a rapid mycologic decrease or eradication of the more susceptible Candida species such as or changes in colonization patterns. Another factor may be azole exposure time or dose. C. albicans, while allowing the less susceptible Candida species (specifically, C. glabrata) to persist and emerge on the Other investigators have demonstrated that one of the most important risk factors for the subsequent development of antifunmucosal surfaces of these patients.
Baseline data revealed a 34% rate of vaginal fungal colonizagal resistance appears to be the antifungal exposure time [28] [29] [30] . Apart from our investigation, there have been no large protion, primarily with C. albicans (in 69% of those colonized). As in previously published studies, in which increased baseline spective studies evaluating specific risk factors for the recovery of non-albicans Candida species from patients with AIDS. It is fungal colonization rates were correlated with lower CD4 / cell counts [22, 25] , our data showed that among patients with a possible that an antifungal prophylaxis study that enrolls patients with low baseline CD4 / cell counts and has a more prolonged 50-cell/mm 3 -lower CD4 / cell count, there was an 11% increase in the vaginal fungal colonization rate. The CD4 / cell count, follow-up period may reveal a more dramatic shift in fungal flora. This shift may be detected as the HIV disease progresses however, had no influence on the relative frequency of Candida species recovered from baseline vaginal cultures. and the patients have more episodes of mucocutaneous candidiasis and thus have repeated exposure to antifungals. An unexpected finding was the low incidence of mixed cultures in each of the treatment groups. Johnson et al. [26] reIn summary, long-term fluconazole prophylaxis (200 mg weekly) influenced and altered the vaginal fungal flora of HIVported that six of 22 patients who receiving long-term fluconazole harbored two species on the same or different occasions.
infected women. A species shift (from the azole-susceptible C. albicans to the more resistant Candida species such as Agabian et al. [27] reported that 12 of 28 women with positive oral and vaginal cultures had different species isolated at the C. glabrata) in the fluconazole-treated patients was demonstrated in this study. This is the first prospective longitudinal two sites. Maenza et al. [28] reported that 30% of patients with AIDS who had positive oral cultures had mixed species study that reveals the selection of C. glabrata in the lower genital tract of HIV-positive women receiving long-term fluisolated. Our finding may reflect the rarity of mixed yeast isolates from the vagina, as opposed to the reports of mixed conazole therapy. The study also demonstrates that the impact of fluconazole on the vaginal mycoflora is seen within the first yeast isolates from the oropharynx.
Several factors may have influenced the low recovery rates 6 months following initiation of prophylaxis. However, despite prolonged fluconazole exposure of up to 29 months, after the of mixed isolates from study patients. These factors may have been a relatively high median CD4 / cell count (180 cells/mm 3 ) initial and early shift of Candida species, the differences between the two study groups did not change further. at study enrollment, the length of exposure to antifungal agents / 9c65$$my18 04-07-99 09:23:47 cida UC: CID
